SKN | Barclays Raises Novo Nordisk Price Target as Strong Earnings Reinforce Wegovy Growth Outlook

Key Takeaways:

• Barclays raised its price target for Novo Nordisk to 310 Danish kroner from 300 Danish kroner while maintaining its Equal Weight rating.
• The revised valuation follows stronger earnings and upgraded full-year guidance, leading Barclays to increase its profit forecasts.
• While the brokerage sees significant potential for oral Wegovy, it believes a limited late-stage pipeline and acquisition uncertainty could temper medium-term upside.

Barclays has raised its price target for Novo Nordisk to 310 Danish kroner from 300 Danish kroner after the pharmaceutical company delivered stronger-than-expected earnings and improved its full-year guidance. Although the brokerage lifted its earnings forecasts to reflect the company’s stronger financial outlook, it maintained its Equal Weight recommendation, suggesting that while operational momentum remains encouraging, longer-term valuation upside may be more balanced.

Stronger Financial Performance Supports Higher Valuation

Novo Nordisk’s latest earnings report exceeded expectations, prompting Barclays to revise its financial projections higher. The upgraded guidance reinforces confidence in the company’s ability to continue delivering solid revenue and profit growth, supported by sustained global demand for its diabetes and obesity therapies.

The improved earnings outlook reflects continued execution across Novo Nordisk’s core business while strengthening investor confidence in its near-term operating performance.

Oral Wegovy Represents a Significant Growth Opportunity

One of the key reasons behind Barclays’ more constructive valuation is the growing opportunity for the tablet version of Wegovy.

The brokerage believes the oral formulation has considerable commercial potential, particularly in markets outside the United States where easier administration could broaden patient adoption. Expanding access through an oral treatment may help Novo Nordisk capture additional market share as demand for obesity therapies continues to increase globally.

This opportunity could complement the company’s existing injectable portfolio while supporting long-term revenue diversification.

Medium-Term Earnings Growth Expected to Moderate

Despite its higher price target, Barclays remains cautious regarding Novo Nordisk’s medium-term earnings trajectory.

The brokerage expects earnings growth to remain positive but relatively modest after the current period of exceptionally strong expansion. As blockbuster products mature, investors are likely to focus increasingly on the company’s ability to introduce new growth drivers capable of sustaining premium valuations.

This balanced outlook underpins Barclays’ decision to retain its Equal Weight rating rather than adopt a more bullish recommendation.

Pipeline Depth Remains an Important Consideration

Barclays also highlighted Novo Nordisk’s relatively thin late-stage research and development pipeline as a factor limiting additional upside.

A strong late-stage pipeline provides visibility into future product launches and long-term earnings growth. While Novo Nordisk continues investing in research and innovation, Barclays believes investors may require greater confidence in the company’s next generation of therapies before assigning significantly higher valuation multiples.

Acquisition Strategy Continues to Create Uncertainty

The brokerage further noted that uncertainty surrounding future acquisitions remains another consideration for investors.

Strategic acquisitions can accelerate product development and strengthen competitive positioning, but they also introduce execution and integration risks. Until there is greater visibility regarding potential transactions, Barclays believes acquisition uncertainty may continue to influence long-term investor sentiment.

Investment Perspective

Novo Nordisk continues to demonstrate operational strength through robust earnings, improved guidance, and sustained demand for its leading obesity and diabetes treatments. Barclays’ higher target price reflects greater confidence in these near-term fundamentals while recognizing the significant commercial opportunity presented by oral Wegovy.

However, maintaining premium valuations over the longer term will likely depend on continued innovation, successful pipeline development, and disciplined capital allocation as competition within the global obesity treatment market intensifies.

Closing Insights

Novo Nordisk remains one of the pharmaceutical industry’s strongest performers, supported by market-leading therapies and improving financial momentum. Barclays’ revised valuation acknowledges these strengths while emphasizing that future shareholder returns will increasingly depend on expanding the company’s innovation pipeline and successfully executing its long-term growth strategy. For investors, the balance between current operational excellence and future product development will remain central to the investment case.

For a confidential discussion regarding retail banking strategy, insurance distribution models, customer loyalty ecosystems, digital financial services, or cross-border financial innovation opportunities, contact our senior advisory team.